Protalix BioTherapeutics Announces First Quarter 2024 Financial and Operating Results May 10, 2024
PR News Wire
Carmiel, Israel, May 3, 2024
The Company will host a conference call and webcast at 8:30 a.m. ET
CARMIEL, Israel , May 3, 2024 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) is focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx. A biopharmaceutical company.® The company, a plant cell-based protein expression system, today announced financial results for the quarter ending March 31, 2024, and said it will provide a business and clinical update on May 10, 2024.
Management plans to host a conference call with investors to discuss financial results and provide an update on recent corporate and regulatory developments.
Conference call details:
date: Friday, May 10, 2024
time: 8:30 a.m. Eastern Daylight Time (EDT)
Free calls: 1-877-423-9813
International: 1-201-689-8573
Israel toll free number: 1 809 406 247
Conference ID: 13745800
Call Us™: https://tinyurl.com/4pkhcxcj
With the Call me™ feature, you no longer have to wait for an operator. Enter your phone number into the platform and the system will call you right away.
Webcast details:
Company link: https://protalixbiotherapeutics.gcs-web.com/events0
Webcast link: https://tinyurl.com/3r8rks24
Conference ID: 13745800
Participants must access the call at least 15 minutes before the meeting to register, download, and install the required audio software. A replay of the conference call will be available for two weeks on the Events Calendar in the Investor section of our website at the link above.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through a proprietary plant cell-based expression system, ProCellEx. The company is the first to receive U.S. Food and Drug Administration (FDA) approval for proteins produced through a plant cell-based suspension expression system. This unique expression system represents a new method for developing recombinant proteins on an industrial scale. Protalix has licensed worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease to Pfizer. This is Protalix's first product manufactured through ProCellEx outside of Brazil, where Protalix retains full rights. His second product from Protalix, Elfabrio®approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici SpA for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets and includes the following product candidates: PRX-115, a plant cell-expressed recombinant pegylated uricase for the treatment of uncontrolled gout. PRX-119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. others.
Logo – https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
Investor contact information
Mike Moyer, Managing Director
Life science advisor
+1-617-308-4306
mmoyer@lifesciadvisors.com
SOURCE Protalix BioTherapeutics, Inc.
